Gregory S. Cameron

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

Craig L. Leonardi, Robert Matheson, Claus Zachariae et al. · New England Journal of Medicine · 2012 · 930 citations · Full text

Medicine, Dermatology, Immunology +17

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

Kenneth B. Gordon, Andrew Blauvelt, Kim Papp et al. · New England Journal of Medicine · 2016 · 838 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

C.E.M. Griffiths, Kristian Reich, Mark Lebwohl et al. · The Lancet · 2015 · 831 citations

Medicine, Immunology, Pharmacotherapy +10

Modulation of Blood Pressure by Central Melanocortinergic Pathways

Jerry R. Greenfield, Jeffrey W. Miller, Julia M. Keogh et al. · New England Journal of Medicine · 2008 · 476 citations · Full text

Life Sciences, Neuroscience, Physiology +14

IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis

James G. Krueger, Scott Fretzin, Mayte Suárez‐Fariñas et al. · Journal of Allergy and Clinical Immunology · 2012 · 380 citations · Full text

Life Sciences, Dermatology, Immunology +14